Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Nephrotic Syndrome 1Nephrosis, Lipoid 1Macular dystrophy, corneal type 1 1Kidney Diseases 1Glomerulosclerosis, Focal Segmental 1

Interventions

Sunitinib 4avelumab 2Nutrition Assessment 2Blood Specimen Collection 2Axitinib 2trifluridine tipiracil drug combination 1trebananib 1spartalizumab 1pembrolizumab 1palbociclib 1etelcalcetide hydrochloride 1enzalutamide 1cabozantinib 1bicalutamide 1atezolizumab 1aldesleukin 1Valsartan 1VMBP protocol 1Stents 1Specimen Handling 1Sorafenib 1Sodium Bicarbonate 1Resistance Training 1Receptors, Androgen 1Plasma Exchange 1Pharmaceutical Preparations 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Nephrotomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Diseases × Adalimumab × Genitourinary × Clear all
NCT04009668 2024-10-30

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

University of Michigan

Phase 2 Completed
7 enrolled 12 charts
Genitourinary

Macular dystrophy, corneal type 1, Glomerulosclerosis, Focal Segmental, Kidney Diseases, Nephrosis, Lipoid, Nephrotic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡